Tricyclo Ring System Having The Six-membered Hetero Ring As One Of The Cyclos Patents (Class 546/79)
  • Patent number: 10138232
    Abstract: The invention relates to compound of the formula (I?) or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: November 27, 2018
    Assignee: NOVARTIS AG
    Inventors: Juergen Reinhardt, Niko Schmiedeberg, Carsten Spanka
  • Patent number: 10011614
    Abstract: Disclosed in the present invention are a bis-?-carboline compound and a preparation method, a pharmaceutical composition and the use thereof. In particular, the bis-?-carboline compound and a pharmaceutical salt thereof are described as general formula I, and the bis-?-carboline compound is prepared through the condensation of ?-carboline intermediate and dihaloalkane. Also disclosed in the present invention are a pharmaceutical composition comprising an effective dose of the bis-?-carboline compound as shown in formula I and a pharmaceutically acceptable carrier, and the use of the bis-?-carboline compound in preparing drugs resistant to tumors such as melanoma, stomach cancer, lung cancer, breast cancer, kidney cancer, liver cancer, oral epidermoid carcinoma, cervical cancer, ovarian cancer, pancreatic cancer, prostate cancer, and colon cancer.
    Type: Grant
    Filed: November 26, 2012
    Date of Patent: July 3, 2018
    Assignee: Xinjiang Huashidan Pharmaceutical Research Co., Ltd
    Inventors: Zihou Wang, Jialin Wu, Jing Shang, Qin Ma, Buxi Shi, Liang Guo, Wenxi Fan, Jie Sun
  • Patent number: 9980947
    Abstract: Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: May 29, 2018
    Assignee: Genentech, Inc.
    Inventors: Sharada Labadie, Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Jason Zbieg, Birong Zhang, Simon Charles Goodacre, Nicholas Charles Ray, Jun Li
  • Patent number: 9975906
    Abstract: The present invention provides the following compound having anti-HIV activity of formula: wherein, A1 is C, CR1A or N; A2 is C, CR2A, or N; A3 is CR3A, CR3AR3B, N, NR3C, O, S, SO, or SO2; A4 is CR4A, CR4AR4B, N, NR4C, O, S, SO, or SO2; A5 is C, CR5A, or N; T1 ring is substituted or unsubstituted monocyclic carbocycle or substituted or unsubstituted monocyclic heterocycle; R1 is halogen, cyano, nitro or —X1—R11; R2 is substituted or unsubstituted alkyl and the like; n is 1 or 2; R3 is hydrogen, substituted or unsubstituted aromatic carbocyclyl; R4 is hydrogen or a carboxy protecting group; the other symbols are as specified in the description.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: May 22, 2018
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Takashi Kawasuji, Daisuke Taniyama, Shuichi Sugiyama, Yoshinori Tamura
  • Patent number: 9908863
    Abstract: The present invention provides compounds of Formula (I) for the treatment of parasitic diseases including malaria, as well as neurodegenerative diseases. Formula (I) wherein R3, R4, X and Y have the meaning given in claim 1.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: March 6, 2018
    Assignee: MERCK PATENT GMBH
    Inventors: Julie Routier, Thomas Spangenberg
  • Patent number: 9856257
    Abstract: The invention related to pyrazolonaphthyridinone derivatives of formula (I) to their preparation and to their therapeutic use as selective inhibitors of type 2 methionine aminopeptidase (hMETAP2).
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: January 2, 2018
    Assignee: SANOFI
    Inventors: Nathalie Guillo, Valérie Martin
  • Patent number: 9809589
    Abstract: The present invention belongs to the technical field of medicines, and relates to a crystal form of a compound used as a mineralocorticoid receptor antagonist and a preparation method therefor, and in particular, to a method for preparing a compound 2-chloro-4-[(3S,3aR)-3-cyclopentyl-7-(4-hydroxypiperidin-1-carbonyl)-3,3a,4,5-tetrahydro-2H-pyrazolo[3,4-f]quinolin-2-yl]benzonitrile of formula (1); a crystal form thereof, a preparation method for the crystal form, and the use of the crystal form in the preparation of drugs for the treatment and/or prevention of renal injury or cardiovascular diseases.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: November 7, 2017
    Assignee: KBP BIOSCIENCES CO., LTD.
    Inventors: Chen Jiang, Aichen Wang, Dedong Zhang
  • Patent number: 9796681
    Abstract: Embodiments of bridged tetrahydroisoquinolines and methods for their use in selectively inhibiting nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 2 are disclosed. The disclosed compounds have a structure according to general formula I or a pharmaceutically acceptable salt thereof: wherein “” represents a single or double bond, R1 is hydrogen, halogen, lower aliphatic, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; Ra is hydrogen, —CH2R2, R3, or —SO2R4; R2 is lower aliphatic, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R3 is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R4 is lower aliphatic, or substituted or unsubstituted aryl; and R5 is hydrogen, halogen, or lower aliphatic.
    Type: Grant
    Filed: May 1, 2014
    Date of Patent: October 24, 2017
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Patrick J. Pagano, Peter Wipf, Maria E. Cifuentes-Pagano, Erin M. Skoda
  • Patent number: 9682954
    Abstract: The present invention relates to the pharmaceutical field, in particular to a phenanthridine derivative as shown in general formula (1) a pharmaceutical composition comprising the derivative, its preparation method, and its uses in manufacture of a medicament for the prevention or treatment of a disease related to the activity of Wnt signaling pathway, hepatitis C and hepatitis B.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: June 20, 2017
    Assignees: Kunming Institute of Botany, The Chinese Academy of Sciences, Shanghai Institutes for Biological Sciences, CAS, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences
    Inventors: Xiaojiang Hao, Duozhi Chen, Lin Li, Zonggen Peng, Jiandong Jiang, Yingtong Di, Junlin Yin, Sheng Wang, Jieyun Cai
  • Patent number: 9598396
    Abstract: The present invention provides compounds of formula (I), their use as inhibitors of tubulin polymerization and their use as PARP inhibitors as well as pharmaceutical compositions comprising said compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7 and Y have defined meanings.
    Type: Grant
    Filed: August 18, 2015
    Date of Patent: March 21, 2017
    Assignee: Janssen Pharmaceutica NV
    Inventors: Patrick Rene Angibaud, Laurence Anne Mevellec, Bruno Roux, Pierre-Henri Storck, Christophe Meyer, Jorge Eduardo Vialard
  • Patent number: 9527875
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
    Type: Grant
    Filed: July 31, 2013
    Date of Patent: December 27, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: William K. Hagmann, Ravi P. Nargund, Timothy A. Blizzard, Hubert Josien, Purakkattle Biju, Christopher W. Plummer, Qun Dang, Bing Li, Derun Li, Linus S. Lin, Mingxiang Cui, Bin Hu, Jinglai Hao, Zhengxia Chen
  • Patent number: 9464086
    Abstract: Crystalline form, Form N-2, of N,Ndicyclopropyl-4-(1,5-dimethyl-1Hpyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide (Compound I) is provided. Also provided are a pharmaceutical composition and an oral dosage form comprising Form N-2 of Compound I as well as a method of using the Form N-2 of Compound I in the treatment of myeloproliferative disorders, which include polycythaemia vera, thrombocythaemia and primary myelofibrosis.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: October 11, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventor: Shella Tameze
  • Patent number: 9452425
    Abstract: An ionic liquid is used as liquid matrix for organic synthesis in homogeneous phase on soluble support, the ionic liquid being presented in liquid or solid form at ambient temperature, of formula A1+X1?, A1+ representing a cation, functional or non-functional, or a mixture of cations in which either none of the cations is functional or at least one of the cations is functional, and X1? an anion, functional or non-functional, or a mixture of anions in which either none of the anions is functional or at least one of the anions is functional.
    Type: Grant
    Filed: May 8, 2009
    Date of Patent: September 27, 2016
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE RENNES 1
    Inventors: Michel Vaultier, Said Gmouh
  • Patent number: 9428500
    Abstract: The present invention relates to inhibitors of the oncogenic protein kinase ALK of formula (I) as herein described and pharmaceutical compositions thereof, as well as to key intermediates towards their synthesis. The compounds of formula (I) are useful in the preparation of a medicament, in particular for the treatment of cancer.
    Type: Grant
    Filed: May 10, 2013
    Date of Patent: August 30, 2016
    Assignees: UNIVERSITA DEGLI STUDI DI MILANO—BICOCCA, UNIVERSITE DE GENEVE, UNIVERSITE CLAUDE BERNARD—LYON
    Inventors: Carlo Gambacorti-Passerini, Luca Mologni, Leonardo Scapozza, William Bisson, Shaheen Ahmed, Peter Goekjian, Sébastien Tardy, Alexandre Orsato, David Gueyrard, Joseph Benoit
  • Patent number: 9428503
    Abstract: The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where Q, R1, R2, R3, R4 and R5 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent ATM kinase mediated disease, including cancer. The specification further relates to crystalline forms of compounds of imidazo[4,5-c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating ATM kinase mediated disease, including cancer, using such compounds and salts.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: August 30, 2016
    Assignee: AstraZeneca AB
    Inventors: Bernard Christophe Barlaam, Kurt Gordon Pike
  • Patent number: 9255096
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: February 9, 2016
    Assignee: Allergan, Inc.
    Inventors: Clarence Eugene Hull, III, Thomas C. Malone
  • Patent number: 9102835
    Abstract: Methods of using dyes and associated technology are provided. A dye, such as a monomeric dye or a dimeric dye, may be used in a nucleic acid gel staining application and/or a nucleic acid detection application. Such a dye and a salt that comprises an anion that is associated with a strong acid and a cation that is associated with a strong base may be used in such an application. A dimeric dye, such as a dimeric dye capable of forming a hairpin-like structure, may be used to stain and/or detect nucleic acids via a release-on-demand mechanism. A dimeric dye having low background fluorescence in the absence of nucleic acids and high fluorescence in the presence of nucleic acids, upon binding therewith, may be used to stain and/or detect nucleic acids.
    Type: Grant
    Filed: August 8, 2013
    Date of Patent: August 11, 2015
    Assignee: BIOTIUM, INC.
    Inventors: Fei Mao, Wai-Yee Leung
  • Patent number: 9040172
    Abstract: The present invention describes novel indenofluorene derivatives which can preferably be employed as matrix materials for phosphorescent dopants or as electron-transport materials, in particular for use in the emission and/or charge-transport layer of electroluminescent devices. The invention furthermore relates to polymers which comprise these compounds as structural units and to a process for the preparation of the compounds according to the invention and to electronic devices which comprise same.
    Type: Grant
    Filed: June 1, 2010
    Date of Patent: May 26, 2015
    Assignee: Merck Patent GmbH
    Inventors: Amir Hossain Parham, Christof Pflumm, Teresa Mujica-Fernaud, Arne Buesing, Holger Heil
  • Patent number: 9040175
    Abstract: The present invention relates to an electronic device comprising at least one organic semiconducting material according to the following formula (I): wherein R1-4 are independently selected from H, halogen, CN, substituted or unsubstituted C1-C20-alkyl or heteroalkyl, C6-C20-aryl or C5-C20-heteroaryl, C1-C20-alkoxy or C6-C20-aryloxy, Ar is selected from substituted or unsubstituted C6-C20-aryl or C5-C20-heteroaryl, and R5 is selected from substituted or unsubstituted C6-C20-aryl or C5-C20-heteroaryl, H, F or formula (II).
    Type: Grant
    Filed: June 8, 2011
    Date of Patent: May 26, 2015
    Assignee: NOVALED AG
    Inventors: Omrane Fadhel, Ramona Pretsch
  • Publication number: 20150133442
    Abstract: The invention features compositions and methods for inhibiting the Pin1 protein, and the treatment of disorders characterized by elevated Pin1 levels.
    Type: Application
    Filed: June 7, 2013
    Publication date: May 14, 2015
    Inventors: Kun Ping Lu, Matthew Brian Boxer, Mindy Irene Emily Davis, Rajan Pragani, Min Shen, Anton Momtchilov Simeonov, Shuo Wei, Xiao Zhen Zhou
  • Patent number: 9017829
    Abstract: The present invention relates to a material for an organic electroluminescent device, including a phenanthrocarbazole-based compound having a specific structure, and an organic electroluminescent device including the same. More specifically, the phenanthrocarbazole-based compound is applied as a material for a phosphorescent and fluorescent organic electroluminescent device, thereby providing an organic light emitting device with improved light emitting efficiency, luminance, thermal stability, driving voltage, lifetime and the like.
    Type: Grant
    Filed: May 6, 2011
    Date of Patent: April 28, 2015
    Assignee: Doosan Corporation
    Inventors: Jin-Seok Hong, Eun Jung Lee, Shin Han Kim, Kyoung-Soo Kim
  • Patent number: 9005777
    Abstract: A heterocyclic compound represented by Formula 1 below, and an organic light-emitting diode including the heterocyclic compound, and a flat display device including the organic light-emitting diode. wherein Ar1 to Ar4, X1, X2, Y1, Y2, L1, and m are defined as in the specification.
    Type: Grant
    Filed: March 7, 2012
    Date of Patent: April 14, 2015
    Assignee: Samsung Display Co., Ltd.
    Inventors: Hye-Jin Jung, Seok-Hwan Hwang, Young-Kook Kim, Jin-O Lim, Sang-Hyun Han, Jong-Hyuk Lee
  • Patent number: 8999526
    Abstract: An organic photoelectric device may include an anode and a cathode configured to face each other, and an active layer between the anode and cathode, wherein the active layer includes a quinacridone derivative and a thiophene derivative having a cyanovinyl group.
    Type: Grant
    Filed: April 13, 2012
    Date of Patent: April 7, 2015
    Assignee: Samsung Electronics Co., Ltd.
    Inventors: Kwang Hee Lee, Kyu Sik Kim, Kyung Bae Park, Dong-Seok Leem, Seon Jeong Lim
  • Patent number: 8987294
    Abstract: The present invention is directed to novel compounds that are able to inhibit the interaction of paxillin or its paralogues, including leupaxin or Hic-5, with alpha.4 integrin or its binding partners that regulate signaling events downstream of the paxillin-.alpha.4 interaction. The present invention further relates to methods for therapeutic use of such compounds and pharmaceutical compositions of such compounds for the treatment of a disease or condition.
    Type: Grant
    Filed: September 15, 2010
    Date of Patent: March 24, 2015
    Assignee: The Regents of the University of California
    Inventors: Mark Ginsberg, Christiane Kummer
  • Patent number: 8986857
    Abstract: Provided is a novel compound which can be used for a transport layer or as a host material or a light-emitting material in a light-emitting element and with which a high-performance light-emitting element can be manufactured. A dibenzo[c,g]carbazole compound in which an aryl group having 14 to 30 carbon atoms and including at least anthracene is bonded to nitrogen of a dibenzo[c,g]carbazole derivative is synthesized. By use of the dibenzo[c,g]carbazole compound, a light-emitting element having very good characteristics can be obtained.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: March 24, 2015
    Assignee: Semiconductor Energy Laboratory Co., Ltd.
    Inventors: Hiroki Suzuki, Satoshi Seo, Sachiko Kawakami, Tsunenori Suzuki
  • Patent number: 8986852
    Abstract: The present invention relates to the compounds of the formula (1) and to organic electroluminescent devices, in particular blue-emitting devices, in which these compounds are used as host material or dopant in the emitting layer and/or as hole-transport material and/or as electron-transport material.
    Type: Grant
    Filed: April 29, 2008
    Date of Patent: March 24, 2015
    Assignee: Merck Patent GmbH
    Inventors: Philipp Stoessel, Arne Buesing, Holger Heil
  • Patent number: 8962157
    Abstract: Compounds of formula I may be used in optoelectronic devices wherein R1, R2 and R4 are, independently at each occurrence, H, a C1-C20 aliphatic radical, a C3-C20 aromatic radical, or a C3-C20 cycloaliphatic radical; R3 is H or a is, independently at each occurrence, 1 or 2; b is, independently at each occurrence, an integer ranging from 0-3; c is, independently at each occurrence, an integer ranging from 0-4; Ar is independently at each occurrence, H, or heteroaryl; and at least two of Ar are heteroaryl.
    Type: Grant
    Filed: August 19, 2009
    Date of Patent: February 24, 2015
    Assignee: General Electric Company
    Inventors: Qing Ye, Jie Liu, Kelly Scott Chichak, Yangang Liang
  • Patent number: 8951647
    Abstract: The present invention relates to organic electroluminescent devices which comprise fluorene derivatives and spirobifluorene derivatives as matrix material for phosphorescent emitters.
    Type: Grant
    Filed: July 8, 2009
    Date of Patent: February 10, 2015
    Assignee: Merck Patent GmbH
    Inventors: Amir Hossain Parham, Joachim Kaiser, Anja Gerhard, Jonas Valentin Kroeber
  • Patent number: 8945703
    Abstract: The invention relates to a polyester film incorporating at least one UV stabilizer of the formula I, in which R1 is hydrogen, alkyl, alkenyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl, or heteroaryl, and R2 is a moiety which contains at least one ?-electron system, which contains a carbon atom and at least one further atom selected from carbon, oxygen, and nitrogen, where the moiety R2 contains at least one atom different from carbon, where the film includes at least one further UV absorber which does not correspond to the formula I. The invention further relates to a process for producing the film, and also to articles formed from the film.
    Type: Grant
    Filed: July 8, 2010
    Date of Patent: February 3, 2015
    Assignee: Mitsubishi Polyester Film GmbH
    Inventors: Holger Kliesch, Oliver Klein, Andreas Bork, Ingo Fischer
  • Publication number: 20150025067
    Abstract: Inhibitors of p67phox protein are provided herein, as well as pharmaceutical compositions and methods relating thereto.
    Type: Application
    Filed: February 13, 2013
    Publication date: January 22, 2015
    Applicant: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: Yi Zheng, Prakash Jagtap, Emily E. Bosco, Jaroslaw Meller, Marie-Dominique Filippi
  • Patent number: 8932732
    Abstract: The present invention relates to organic electroluminescent devices, in particular blue-emitting devices, in which compounds of the formulae (1) to (4) are used as host material or dopant in the emitting layer and/or as hole-transport material and/or as electron-transport material.
    Type: Grant
    Filed: May 3, 2007
    Date of Patent: January 13, 2015
    Assignee: Merck Patent GmbH
    Inventors: Arne Buesing, Philipp Stoessel, Holger Heil
  • Patent number: 8932734
    Abstract: Compounds comprising a 3,9-linked oligocarbazole moiety and a dibenzothiophene, dibenzofuran, dibenzoselenophene, aza-dibenzothiophene, aza-dibenzofuran, or aza-dibenzoselenophene are provided. The 3,9-linked oligocarbazole and dibenzo or aza-dibenzo moiety are separated by an aromatic spacer. The compounds may be used as non-emissive materials for phosphorescent OLEDs to provide devise having improved performance.
    Type: Grant
    Filed: October 8, 2010
    Date of Patent: January 13, 2015
    Assignee: Universal Display Corporation
    Inventor: Alexey Dyatkin
  • Patent number: 8927117
    Abstract: The present invention relates to a compound of the formula (1) and (2) The invention further relates to a process to produce the compound. The invention additionally relates and an electronic device containing the compound of the formula (1) or (2). The electronic device can be an organic electroluminescence devices, particularly a blue emitting device, in which compounds are used as host materials or dopants in the emitting layer and/or as hole transport materials and/or as electron transport materials.
    Type: Grant
    Filed: March 17, 2009
    Date of Patent: January 6, 2015
    Assignee: Merck Patent GmbH
    Inventors: Arne Buesing, Holger Heil, Philipp Stoessel
  • Patent number: 8927121
    Abstract: Disclosed herein are compounds represented by Formula 1, wherein R1, Ar1, X, Ar2, Ar3, and Het are described herein. Compositions and light-emitting devices related thereto are also disclosed.
    Type: Grant
    Filed: June 24, 2013
    Date of Patent: January 6, 2015
    Assignee: Nitto Denko Corporation
    Inventors: Shijun Zheng, Jensen Cayas, Sheng Li, Amane Mochizuki, Hyun Sik Chae, Brett T. Harding
  • Patent number: 8927119
    Abstract: There is provided an organic compound having excellent characteristics, including excellent electron-injecting/transporting performance, hole blocking ability, and high stability in the thin-film state, for use as material of an organic electroluminescent device having high efficiency and high durability. There is also provided a high-efficient and high-durable organic electroluminescent device using the compound. The compound is represented by general formula (1) having a substituted anthracene ring structure and a pyridoindole ring structure. The organic electroluminescent device includes a pair of electrodes, and one or more organic layers sandwiched between the pair of electrodes, and the compound is used as a constituent material of at least one organic layer.
    Type: Grant
    Filed: July 28, 2010
    Date of Patent: January 6, 2015
    Assignee: Hodogaya Chemical Co., Ltd.
    Inventors: Norimasa Yokoyama, Shuichi Hayashi, Naoaki Kabasawa, Daizou Kanda, Shigeru Kusano
  • Patent number: 8895581
    Abstract: The present invention encompasses compounds of general formula (1), wherein the groups R1 to R7, Qa, Qb, L, n and m are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, pharmaceutical preparations containing such compounds and their use as medicaments.
    Type: Grant
    Filed: May 17, 2011
    Date of Patent: November 25, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Darryl McConnell, Harald Engelhardt, Christiane Kofink
  • Patent number: 8895744
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2 and R3 are as defined in the description, to their pharmaceutical compositions and use thereof for the treatment of cancer expressing oncogenic ALK protein, particularly anaplastic large cell lymphoma (ALCL), diffuse large B cell lymphoma (DLBCL), inflammatory myofibroblastic tumors (IMT) and non-small cell lung cancer (NSCLC).
    Type: Grant
    Filed: August 27, 2009
    Date of Patent: November 25, 2014
    Assignees: Universita' Degli Studi di Milano-Bicocca, Universite' de Geneve, Universite' Claude Bernard de Lyon 1
    Inventors: Carlo Gambacorti Passerini, Luca Mologni, Leonardo Scapozza, Shaheen Ahmed, Peter G. Goekjian, David Gueyrard, Florence Popowycz, Benoit Joseph, Cedric Schneider, Pierre Garcia
  • Patent number: 8889707
    Abstract: The invention discloses methods for preventing or treating addiction by administering to a subject in need thereof a PARP inhibitor.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: November 18, 2014
    Inventor: Malka Cohen-Armon
  • Patent number: 8889271
    Abstract: Disclosed are a novel-structural compound including a 5-membered heterocycle, an organic electronic device using the same, and a terminal thereof.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: November 18, 2014
    Assignees: Duksan High Metal Co., Ltd., Samsung Mobile Display Co., Ltd.
    Inventors: Junghwan Park, Daesung Kim, Jungcheol Park, Kiwon Kim, Jinuk Ju, Jangyeol Baek, Soungyun Mun, Yongwook Park, Hwasoon Jung, Wonsam Kim, Jihun Byun, Sungjin Park, Eunkyung Kim, Daehyuk Choi, Dongha Kim, Hansung Yu, Kwanhee Lee, Taeshick Kim, Daeyup Shin, Mikyung Kim, Dongheon Kim
  • Patent number: 8889866
    Abstract: The present invention provides compounds of formula (I), their use as inhibitors of tubulin polymerization and their use as PARP inhibitors as well as pharmaceutical compositions comprising said compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7 and Y have defined meanings.
    Type: Grant
    Filed: March 26, 2009
    Date of Patent: November 18, 2014
    Assignee: Janssen Pharmaceutica, NV
    Inventors: Patrick René Angibaud, Laurence Anne Mevellec, Bruno Roux, Pierre-Henri Storck, Christophe Meyer, Jorge Eduardo Vialard
  • Patent number: 8859113
    Abstract: The present invention relates to novel carbazole derivatives and an organic light-emitting diode device using the same. These carbazole derivatives can simultaneously or singly be used as a hole transporting layer, a host or guest of an emitting layer or an electron transporting layer of an organic light-emitting diode device.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: October 14, 2014
    Assignee: China Petrochemical Development Corporation
    Inventors: Hsian Chan Liu, Min Sheng Chen, Chin Yi Lee
  • Patent number: 8841453
    Abstract: The invention relates to novel hybrid cholinesterase inhibitors containing the melatonin or its oxidation products unit and tetrahydroacridine unit linked via a carbamate bond. Due to the high selectivity of action, which is expressed with high ratio of IC50 for acetylcholinesterase inhibition to IC50 for butyrylcholinesterase inhibition ([IC50(AChE)]/[IC50(BChE)]), the novel compounds may be used in relief and/or treatment of the neurodegenerative diseases, among them the Alzheimer's disease.
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: September 23, 2014
    Assignees: Uniwersytet Warszawski, Centrum Medyczne Ksztalcenia Podyplomowego
    Inventors: Anna Zawadzka, Zbigniew Czarnocki, Iwona Lozinska, Zuzanna Moleda, Miroslawa Panasiewicz
  • Patent number: 8835022
    Abstract: Disclosed are a metal complex compound represented by the following Chemical Formula 1 or 3, and an organic light emitting diode device including the same. In Chemical Formulae 1 and 3, M1, M2, R1 to R14, y1 and y2 are as defined in the detailed description.
    Type: Grant
    Filed: July 12, 2011
    Date of Patent: September 16, 2014
    Assignee: Samsung Display Co., Ltd.
    Inventors: Yuji Hamada, Kwan-Hee Lee
  • Patent number: 8828561
    Abstract: A compound for an organic photoelectric device, the compound being represented by the following Chemical Formula (“CF”) 1:
    Type: Grant
    Filed: July 23, 2012
    Date of Patent: September 9, 2014
    Assignee: Cheil Industries, Inc.
    Inventors: Hyung-Sun Kim, Eun-Sun Yu, Young-Hoon Kim, Ja-Hyun Kim, Soo-Hyun Min, Ho-Jae Lee, Eui-Su Kang, Mi-Young Chae
  • Patent number: 8829023
    Abstract: The invention relates to a process for obtaining compounds derived from tetrahydro-?-carboline, specifically tadalafil and intermediate products from the synthesis, comprising the reaction between piperonal and an alkyl ester of D-tryptophan as a salt, and in the absence of any other component, followed by haloacetylation and a final cyclization with methylamine.
    Type: Grant
    Filed: February 10, 2012
    Date of Patent: September 9, 2014
    Assignee: Interquim, S.A.
    Inventors: Xavier Berzosa Rodríguez, Francisco Marquillas Olondriz
  • Patent number: 8785001
    Abstract: The present invention relates to mixtures of organic materials, to the use of these mixtures in organic electroluminescent devices, and to organic electroluminescent devices comprising these mixtures.
    Type: Grant
    Filed: November 17, 2006
    Date of Patent: July 22, 2014
    Assignee: Merck Patent GmbH
    Inventors: Horst Vestweber, Philipp Stoessel, Holger Heil
  • Patent number: 8785003
    Abstract: An organic EL device material includes at least a unit including 3,5-biscarbazolylphenyl group, a unit including 4-carbazolylphenyl group, and a compound including a unit including a nitrogen-containing aromatic heterocyclic ring bonding the unit including 3,5-biscarbazolylphenyl group and the unit including 4-carbazolylphenyl group.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: July 22, 2014
    Assignee: Idemtisu Kosan Co., Ltd.
    Inventors: Tetsuya Inoue, Kumiko Hibino, Kei Yoshida, Kazuki Nishimura, Toshihiro Iwakuma
  • Patent number: 8771840
    Abstract: Provided are a heterocyclic compound which emits blue light and is represented by General Formula (G1) below, and a light-emitting element, a light-emitting device, an electronic device and a lighting device which are formed using the heterocyclic compound represented by General Formula (G1) below. The use of the heterocyclic compound represented by General Formula (G1) makes it possible to provide a light-emitting element which has high emission efficiency, and also a light-emitting device, an electronic device and a lighting device which have reduced power consumption.
    Type: Grant
    Filed: November 9, 2010
    Date of Patent: July 8, 2014
    Assignee: Semiconductor Energy Laboratory Co., Ltd.
    Inventors: Hiroki Suzuki, Tsunenori Suzuki, Satoshi Seo
  • Patent number: 8771844
    Abstract: A heterocyclic compound, an organic light-emitting diode, and a flat display device, the heterocyclic compound being represented by Formula 1, below:
    Type: Grant
    Filed: December 6, 2011
    Date of Patent: July 8, 2014
    Assignee: Samsung Display Co., Ltd.
    Inventors: Young-Kook Kim, Seok-Hwan Hwang, Hye-Jin Jung, Jin-O Lim, Sang-Hyun Han, Yoon-Hyun Kwak, Sun-Young Lee, Se-Jin Cho, Jong-Hyuk Lee, Sung-Chul Kim
  • Patent number: RE45216
    Abstract: An organic electroluminescent element including at least an emission layer sandwiched between an anode and a cathode, wherein the emission layer comprises at least a compound represented by Formula (A),
    Type: Grant
    Filed: September 25, 2012
    Date of Patent: October 28, 2014
    Assignee: Konica Minolta Holdings, Inc.
    Inventors: Tatsuo Tanaka, Hideo Taka